KLOW Peptide Dosage — Research Context and Component Pharmacokinetics
The short version — what the dosage research actually shows
KLOW peptide dosage is an unanswered research question. The four-peptide blend has never been tested in a human clinical trial or a controlled animal study, so there is no validated dose for the combination. What exists is a canonical research-vial composition (80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg) and a collection of component-level doses from the individual constituent studies — rodent doses that cannot be directly translated to humans and that were measured for each peptide alone, not in co-formulation.
This page describes the vial composition, the component doses studied in the research literature, and the pharmacokinetic reasons a single co-formulated vial cannot hold all four components at matched exposures simultaneously. No human dose is stated here, because none exists.
KLOW peptide dosage — the vial composition
The most widely cited research-vial composition for KLOW is 80 mg total co-formulated in one lyophilized vial: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. This is the 50/10/10/10 ratio. The four peptides are co-dissolved in the vial; they do not form a single new molecule and do not chemically interact in any documented sense (though the potential for copper-redox chemistry in a solution containing GHK-Cu alongside three other peptides has not been formally characterized).
The vial is reconstituted with bacteriostatic water for laboratory handling. Subcutaneous injection is the route described in most research-handling contexts; the component literature also covers topical application (GHK-Cu), oral and targeted delivery (KPV, BPC-157), and intra-articular injection (BPC-157) — routes that have been studied for single constituents, not for the blend.
KLOW dosage — component doses in the research literature
Because no human dosing exists for the KLOW blend, the following documents the doses at which each constituent was measured in the studies that produced the key findings — for research context only, not as a dosing recommendation.
KPV. In Dalmasso et al. (2008) [3]: 10 nM (nanomolar) in human intestinal epithelial cell culture for NF-kB and MAPK assays; 100 micromolar in mouse drinking water for the colitis-model studies. The in vivo oral dose was delivered via drinking water, exploiting PepT1-mediated gut uptake. The in vitro concentrations are cell-culture quantities; the in vivo oral concentrations are far higher, reflecting the delivery challenge of getting a tripeptide to its target cells intact.
GHK-Cu. In Pickart et al. (2015) [4]: topical formulations for the clinical skin studies; 1–10 nanomolar for the in vitro collagen-synthesis assays. The bioinformatic gene-expression analysis in Pickart & Margolina (2018) [5] was performed with 1–10 nM for cell-culture validation. The cosmetic literature uses topical formulations with concentrations varying widely across products — these are concentration studies for topical application, not systemic doses.
BPC-157. In Staresinic et al. (2003) [2]: 10 micrograms, 10 nanograms, or 10 picograms per rat (intraperitoneal, once daily). Efficacy was apparent across all three dose levels — a seven-order-of-magnitude range with consistent directional effects. The 2025 human IV safety pilot [6] used 10 mg on day 1 and 20 mg on day 2 in 250 mL saline as a 1-hour intravenous infusion in two adults — a safety pilot, not a dose-finding study.
TB-500 / Tβ4. In Malinda et al. (1999) [1]: topical and intraperitoneal Tβ4 in rat wound models; ~10 picograms was the active concentration in keratinocyte migration assays. Philp et al. (2004) [11]: nanomolar concentrations in the follicle-stem-cell studies. These are doses for the full-length 43-amino-acid native Tβ4, not for the short synthetic TB-500 fragment; the pharmacology of the fragment at equivalent doses is not characterized in the same way.
KLOW peptide dosage and frequency — the pharmacokinetic mismatch
The most structurally important dosage fact about KLOW is the pharmacokinetic mismatch inherent in the co-formulation. The four peptides have markedly different half-lives and clearance rates: the tripeptides KPV and GHK-Cu are small (MW 342 and 403 Da) and clear very quickly in plasma; BPC-157 is larger (MW 1419 Da) and has a short reported elimination half-life; TB-500 as the short heptapeptide fragment behaves differently from the full-length 43-amino-acid native Tβ4 whose pharmacokinetics are better characterized.
A pharmacokinetic mismatch (when co-formulated compounds have very different absorption and clearance rates) means a single co-formulated dose cannot hold all four components at matched exposures simultaneously. The peak plasma concentration of the tripeptides arrives and clears before the larger peptides reach their own peak. No study has characterized the pharmacokinetics of the four-peptide combination, and no dosing schedule has been validated that addresses this mismatch.
This is not a rhetorical point; it is a structural fact about the co-formulation that belongs in any honest discussion of KLOW dosage and frequency. The individual constituent doses from rodent models are presented in the section above for research context — they are not combinable into a validated 'KLOW dose.'
KLOW dosage context — stability and reconstitution
The lyophilized (freeze-dried) KLOW blend is described in research-handling contexts as reconstituted with bacteriostatic water and typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry — meaning it can accept or donate electrons in solution — which is a theoretical compatibility consideration when co-dissolved with three other peptides in one vial. This has not been formally characterized for the KLOW mixture. The stability of the individual peptides post-reconstitution varies; GHK-Cu's copper chelate introduces a chemistry that the other three constituents do not.
For KLOW research on mechanisms, and for the component citations that underlie the dosage figures above, see the research and references pages.